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The synthesis of human immunodeficiency virus type 1 (HIV-1) mRNAs is a complex process by which more
than 30 different mRNA species are produced by alternative splicing of a single primary RNA transcript. HIV-1
splice sites are used with significantly different efficiencies, resulting in different levels of mRNA species in
infected cells. Splicing of Tat mRNA, which is present at relatively low levels in infected cells, is repressed by
the presence of exonic splicing silencers (ESS) within the two tat coding exons (ESS2 and ESS3). These ESS
elements contain the consensus sequence PyUAG. Here we show that the efficiency of splicing at 3* splice site
A2, which is used to generate Vpr mRNA, is also regulated by the presence of an ESS (ESSV), which has
sequence homology to ESS2 and ESS3. Mutagenesis of the three PyUAG motifs within ESSV increases splicing
at splice site A2, resulting in increased Vpr mRNA levels and reduced skipping of the noncoding exon flanked
by A2 and D3. The increase in Vpr mRNA levels and the reduced skipping also occur when splice site D3 is
mutated toward the consensus sequence. By in vitro splicing assays, we show that ESSV represses splicing when
placed downstream of a heterologous splice site. A1, A1B, A2, and B1 hnRNPs preferentially bind to ESSV RNA
compared to ESSV mutant RNA. Each of these proteins, when added back to HeLa cell nuclear extracts
depleted of ESSV-binding factors, is able to restore splicing repression. The results suggest that coordinate
repression of HIV-1 RNA splicing is mediated by members of the hnRNP A/B protein family.
Both simple and complex retroviruses require splicing of a
single primary RNA transcript in order to generate mRNA for
the viral envelope protein (Env). Complex retroviruses, such as
human immunodeficiency virus type 1 (HIV-1), require the
production of additional mRNAs for regulatory and accessory
proteins. For HIV-1 these include mRNAs for Tat, Rev, Vif,
Vpr, and Nef (6, 19, 35, 37, 39). The Rev protein binds to
RNAs containing the Rev-responsive element in the env gene
sequence. This interaction facilitates nuclear export of un-
spliced and partially spliced RNAs required for translation and
for packaging into progeny virions (16, 17, 20, 21, 30; for a
recent review, see reference 12). Early in infection of cells with
HIV-1 and prior to the accumulation of Rev, multiply spliced
mRNAs predominate in the cytoplasm. Later in infection, the
production of Rev allows the cytoplasmic accumulation of un-
spliced and partially spliced RNAs (24, 25)
In order to generate mRNAs required for the synthesis of
viral proteins, HIV-1 primary RNA transcripts undergo a com-
plex splicing process (Fig. 1). The viral RNA contains both
constitutive and alternative 59 and 39 splice sites. All spliced
mRNAs contain 59-terminal noncoding exon 1, which is
flanked by consensus 59 splice site D1. Selection of the alter-
native 39 splice sites near the middle of the genome determines
which proteins are encoded by the mRNAs. Two size classes of
spliced RNAs are produced, depending on the removal of the
intron spanning D4 to A7 (;1.8 kb for the small size class and
;4 kb for the intermediate size class). For instance, splicing at
A3 coupled with splicing at D4 to A7 generates ;1.8-kb Tat
mRNA. Similarly, splicing at A4a, A4b, or A4c coupled with
splicing at D4 to A7 generates ;1.8-kb Rev mRNA; splicing at
A5 coupled with splicing at D4 to A7 generates ;1.8-kb Nef
mRNA. Splicing at A3 generates an ;4-kb mRNA encoding a
single-exon form of Tat. Splicing of mRNAs at A4a, A4b, A4c,
and A5 generates ;4-kb mRNAs encoding Env. Splicing at A1
and A2 generates ;4-kb mRNAs encoding Vif and Vpr, re-
spectively. As a further complexity, some mRNAs of both size
classes include one or both of two alternative noncoding exons
(Fig. 1B): exon 2, which is flanked by A1 and D2, and exon 3,
which is flanked by A2 and D3 (18, 35, 39). Finally, some virus
strains contain within the env gene cryptic splice sites (D5 and
A6) whose usage results in the synthesis of an mRNA encoding
a hybrid protein, Tev (8, 38).
Different spliced HIV-1 mRNAs are generated with very
different efficiencies. For example, ;1.8-kb mRNAs encoding
Tat are present at low levels compared to mRNAs encoding
Rev or Nef. Similarly, ;4-kb mRNAs encoding single-exon Tat
are present at low levels compared to mRNAs encoding Env
(35). It was previously shown that splice site A3 is repressed by
ESS2, an exonic splicing silencer (ESS) within the first tat
coding exon (exon 4 in Fig. 1). Mutations within the ESS2
element result in a selective increase in splicing at A3 (3, 4). A
second ESS (ESS3) was identified within the second tat/rev
coding exon downstream of A7 (exon 7 in Fig. 1). In this case,
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an adjacent upstream exonic splicing enhancer is juxtaposed to
the ESS (4, 43). Both ESS2 and ESS3 appear to bind to a
common cellular factor or factors that act to repress splicing
(42). It has been reported that ESS2 selectively binds to mem-
bers of the A/B hnRNP family (hnRNPs A1, A1B, A2, and B1)
(11, 14). The addition of hnRNP A1 and other members of the
hnRNP A/B protein family restores specific splicing repression
in HeLa cell nuclear extracts depleted of ESS2-binding pro-
teins (11). A third potential ESS is present in the env gene,
where it may prevent the activation of cryptic exon 6D, which
is bordered by splice sites A6 and D5 (46).
The levels of Vpr mRNA singly spliced at 39 splice site A2
also have been shown to be low in cells infected with HIV-1,
indicating that splicing at A2 is inefficient. Furthermore, non-
coding exon 3 (Fig. 1) is skipped in the majority of the mRNAs
(35). This exon skipping also suggests that splice site A2 or D3
or both of these splice sites are used inefficiently. It has been
shown that the branch point used for splicing at splice site A2
is a G rather than the consensus A that is used for most 39
splice sites. However, replacing the nonconsensus wild-type
branch-point sequence with a consensus sequence did not sig-
nificantly affect splicing efficiency in an in vitro splicing system
(13). In this report, we describe additional elements down-
stream of 39 splice site A2 that act to repress splicing at this
splice site.
MATERIALS AND METHODS
Plasmids. Infectious HIV-1 plasmid pNL4-3 (GenBank accession no.
M19921) was constructed by Adachi et al. (1) and was obtained from the Na-
tional Institutes of Health AIDS Research and Reference Reagent Program.
Plasmid pDPSP is a derivative of pNL4-3 with a deletion between the SpeI site at
nucleotide (nt) 1511 and the BalI site at nt 4551 (23). Mutant plasmid pSPRS,
with base changes within noncoding exon 3, was constructed by PCR mutagenesis
using a Quickchange mutagenesis kit (Stratagene, La Jolla, Calif.). The muta-
genic primers were NL43PSMTF (59GAAATACCATATTCTGACGTATAGT
TCTTCCTCTGTGTGAATATCAAGC) and NL43PSMTR (59GCTTGATATT
CACACAGAGGAAGAACTATACGTCAGAATATGGTATTTC); the changed
nucleotides are underlined. Mutant plasmid pSPD3up, with an A-to-T change at
position 16 of the D3 splice site, was generated by PCR mutagenesis using the
Quickchange mutagenesis kit. The mutagenic primers were D3ATF (59GGAC
ATAACAAGGTAGGTTCTCTACAGTACTTGG39) and D3ATR (59CCAAG
TACTGTAGAGAACCTACCTTGTTATGTCC39). Plasmid pHS1-X, used as a
template to synthesize substrates for the splicing assays, has been described
previously (3). Plasmid pHS3-ESSV was constructed by replacing the EcoRI-
ScaI fragment of pHS1-X with nt 5322 to nt 5479 of pNL4-3. Mutant plasmid
pHS3-ESSVx was created by replacing the region between the EcoRI and XhoI
sites of pHS3-ESSV with mutated PCR products. The mutated PCR products
were synthesized by using a modified megaprimer technique (2). The mutagenic
primers were PSALLF (59CCATATTCTGACGTATAGTTCTTCCTCTGTGT
GAA) and PSALLR (59TTCACACAGAGGAAGAACTATACGTCAGAATA
TGG). pHS1-ESSV and pHS1-ESSVx are derivatives of pHS1-X which have
wild-type and mutant noncoding exon 3 silencers inserted in place of the tat exon
2 ESS2, respectively. pHS1-ESSV and pHS1-ESSVx were generated by PCR
mutagenesis using the primers PSWTS (59TTAGGACGTATAGTTAGTCCT
AGGGGAAGCATCCAGGAAGTC) and PSWTA (59CCTAGGACTAAC
TATACGTCCTAAACTGGCTCCATTTCTTGC) for pHS1-ESSV and the
FIG. 1. (A) Structure of the HIV-1 NL4-3 genome. Boxes indicate open reading frames. Hash marks represent endpoints of gag-pol deletion
in pDPSP. ESS sequences are shown by shaded boxes. Oligonucleotide primers used are indicated by arrows designating position and orientation.
LTR, long terminal repeat. (B) Structures of the small (;1.8-kb) and intermediate (;4.0-kb) size classes of HIV-1 transcripts. Exons are indicated
as black bars. The exons within the different RNA species are designated by numbers (and sometimes letters) within the boxes according to the
nomenclature of Purcell and Martin (35). The exon designations with the letter I indicate exons present only in the intermediate-size HIV-1 mRNA
species. The alternative noncoding exons 2 and 3 are indicated with asterisks. Locations of 59 (D) and 39 (A) splice sites are shown.
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primers PSMTS (59TTCTGACGTATAGTTCTTCCTCTGGGAAGCATCCA
GGAAGTC) and PSMTA (59CAGAGGAAGAACTATACGTCAGAAACTG
GCTCCATTTCTTGC) for pHS1-ESSVx. The resulting PCR products were
used as primers for the synthesis of a larger product by a modified megaprimer
technique (2). This PCR product was ligated into pHS1-X cleaved with EcoRI
and KpnI. The competitor RNAs used for depleting nuclear extracts were tran-
scribed from linearized plasmids pESS2, pESS2x, pESSV, and pESSVx. pESS2
and pESS2x were created by insertion of 109-bp AccI-RsaI fragments from pHS1
and pDESS10 (4) into pBluescript SK(1) (Stratagene) cleaved with AccI and
EcoRI, respectively. pESSV and pESSVx were created similarly using AccI-RsaI
fragments from pHS1-ESSV and pHS1-ESSVx, respectively.
RNA isolation, reverse transcription, and PCR. Total cellular RNA was iso-
lated from transfected HeLa cells 48 h posttransfection by extraction with Tri-
Reagent (Molecular Research Center, Inc.) according to procedures supplied by
the manufacturer. Three micrograms of RNA was reverse transcribed for 1 h in
a 30-ml total volume containing 20 mM each deoxynucleoside triphosphate, 20 U
of RNasin (Promega, Madison, Wis.), 100 pmol of random hexamer (Pharmacia,
Piscataway, N.J.), 6 mg of bovine serum albumin, and 200 U of Moloney murine
leukemia virus reverse transcriptase (RT) (Life Technologies/Gibco/BRL, Rock-
ville, Md.).
For the semiquantitative analysis of ;1.8-kb HIV-1 mRNAs, PCR of cDNA
was performed with forward oligonucleotide primer BSS (59GGCTTGCTGAA
GCGCGCACGGCAAGAGG; nt 700 to nt 727) and reverse primer SJ4.7A,
which spans splice sites D5 and A7 (59TTGGGAGGTGGGTTGCTTTGATAG
AG; nt 8381 to nt 8369 and nt 6044 to nt 6032). Reverse primer KPNA (59AG
AGTGGTGGTTGCTTCCTTCCACACAG) was used with forward primer BSS
for the analysis of ;4.0-kb HIV-1 mRNAs (34). PCR amplification was per-
formed essentially as previously described (10). Thirty cycles of PCR (94°C for
30 s, 60°C for 1 min, and 72°C for 2 min) were completed with a total reaction
volume of 50 ml containing 75 mM MgCl2, 10 mM each deoxynucleoside triphos-
phate, 25 pmol of each primer, and 0.1 U of Perkin-Elmer Amplitaq Gold
polymerase. Prior to PCR, the reaction mixture was denatured for 5 min at 94°C.
After confirmation of the amplified spliced product by polyacrylamide gel elec-
trophoresis (PAGE) and ethidium bromide staining, products (100 ng) were
radiolabeled by performing a single round of PCR with the addition of 10 mCi of
[32P]dCTP. Radiolabeled products were analyzed by denaturing electrophoresis
on 6% polyacrylamide–7 M urea gels.
RNA substrate synthesis. To prepare transcription templates, all DNA con-
structs were linearized with XhoI. In vitro transcription of runoff RNA transcripts
labeled with [32P]UTP (NEN, Boston, Mass.) was carried out as previously
described (3).
Immobilization of RNA and depletion of HeLa cell nuclear extracts. Substrate
RNAs for bead immobilization were synthesized by in vitro transcription using
T7 RNA polymerase (Ambion, Austin, Tex.) and biotin-14 CTP (Life Technol-
ogies/Gibco/BRL) with a ratio of modified nucleotide to standard nucleotide of
1:2. RNAs were noncovalently linked to Dynabeads M-280–streptavidin (6.7 3
108 beads/ml) (Dynal, Lake Success, N.Y.) as suggested by the manufacturer.
Two micrograms of RNA was incubated with 40 ml of Dynabeads in 1 M
NaCl–10 mM Tris HCl (pH 7.5)–1 mM EDTA at room temperature for 15 min
with gentle agitation. The Dynabeads with immobilized RNA were washed two
times with Dignam’s buffer D (15) and then incubated with 15 ml of HeLa cell
nuclear extract for 15 min at 30°C with gentle agitation. Nuclear extract depleted
of bound factors was separated from the Dynabeads-RNA complex by collecting
the complex with a Dynal magnetic particle concentrator for 1 min.
In vitro splicing. Splicing reactions were carried out essentially as previously
described (3). In brief, approximately 8 fmol of 32P-labeled RNA was incubated
for 2 h at 30°C in a solution containing 60% (vol/vol) nuclear extract in Dignam’s
buffer D, 20 mM creatine phosphate, 3 mM MgCl2, 0.8 mM ATP, and 2.6%
(wt/vol) polyvinyl alcohol. The final volume of the splicing reaction mixture was
25 ml.
Protein analysis. Proteins were separated by sodium dodecyl sulfate (SDS)–
10% PAGE and visualized by Coomassie blue staining or transferred by elec-
troblotting to nitrocellulose for immunoblot analysis. Monoclonal antibody 4B10
against hnRNP A1, which also detects hnRNP A1B, was provided by G. Dreyfuss
(University of Pennsylvania) and used at a concentration of 1:3,000. Monoclonal
antibody 2B2 against hnRNP B1 was provided by H. Kamma (University of
Tsukuba, Ibaraki, Japan) and used at a concentration of 1:3,000. Rabbit poly-
clonal anti-A2 antiserum, which also cross-reacts with hnRNP A1, was provided
by S. Riva (Istituto di Genetica Biochimica and Evoluzionistica, Pavia, Italy). It
was used at a concentration of 1:1,000. Immunoblots were developed using an
alkaline phosphatase staining kit (Vector Labs, Burlingame, Calif.).
Preparation of A/B hnRNPs and adding back to depleted extracts. Recombi-
nant hnRNPs A1, A1B, A2, and B1 were expressed in Escherichia coli and
purified as described previously (32, 33). Glutathione S-transferase (GST)–UP1
and GST plasmids (obtained from X. Zhang, University of Arkansas) were
expressed in E. coli and lysed by sonication, and the proteins were purified by
binding to and elution with glutathione-Sepharose beads (Pharmacia). Proteins
were added to depleted nuclear extracts, and splicing was carried out for 2 h at
30°C.
RESULTS
Mutagenesis of 5* splice site D3 toward the consensus 5*
splice site sequence increases splicing at 3* splice site A2. We
first investigated elements affecting the efficiency of splicing at
HIV-1 splice site A2 in HeLa cell cultures transfected with an
HIV-1 genomic deletion construct (pDPSP; Fig. 1). It has been
shown that the splicing of pDPSP RNA transcripts does not
differ significantly from that of wild-type HIV-1 (23). Also, it
has been shown that HIV-1 RNAs are spliced identically in
transfected HeLa cells and infected peripheral blood mononu-
clear cells (35). Splice site D3 (AG/GUAGGA) differs at po-
sitions 14 and 16 from the mammalian consensus 59 splice site
sequence.
We first tested whether improving this 59 splice site would
increase the efficiency of splicing at splice site A2. Thus, posi-
tion 16 of splice site D3 was changed from A to U to improve
the match to the consensus 59 splice site sequence. HeLa
cells were transfected with wild-type (pDPSP) and mutant
(pSPD3up) constructs, and total RNA was isolated from the
cells at 48 h after transfection. Using appropriate oligonucle-
otide primers, RNA was analyzed by RT-PCR for the relative
levels of individual mRNAs of both intermediate (;4.0 kb)
and small (;1.8 kb) sizes (Fig. 2). The nomenclature for the
mRNAs denotes which exons are present in the particular
mRNA species (Fig. 1B). The results for the ;4.0-kb RNA size
class indicated that there was a significant increase in the level
of singly spliced Vpr mRNA (1.3I) when 59 splice site D3 was
improved (compare lanes 2 and 3 of Fig. 2A). In addition,
there were dramatic increases in the levels of ;4.0-kb Env
mRNA species that include noncoding exon 3 (1.3.5I, 1.3.4aI/
1.3.4bI, and 1.2.3.5I) and a relative decrease in the major singly
spliced species, 1.5I, as well as species 1.2.5I, which includes
only noncoding exon 2.
This shift to mRNA species that include exon 3 was also
observed with the mutant in the ;1.8-kb mRNA size class
(compare lanes 2 and 3 of Fig. 2B). Increases in the levels of
1.3.5.7, 1.3.4b.7, 1.3.4a.7, 1.2.3.5.7, 1.2.3.4b.7, 1.2.3.4a.7, and
1.3.4.7 mRNAs, all of which include exon 3, were observed.
These increases were concomitant with relative decreases in
the levels of 1.5.7, 1.4b.7, and 1.4a.7, which exclude both non-
coding exons, and 1.2.5.7, which includes only exon 2. These
results indicate that in wild-type HIV-1 RNA, the nonconsen-
sus 59 splice site D3 bordering the 39 end of noncoding exon 3
affects the splicing efficiency of splice site A2 bordering the 59
end of this exon. The presence of nonconsensus 59 splice site
D3 also results in the skipping of noncoding exon 3 in the
majority of the HIV-1 mRNAs.
Mutations within a putative ESS element in exon 3 increase
splicing at 3* splice site A2. Since it appeared from the above
data that the optimization of 59 splice site D3 resulted in only
partial relief of exon 3 skipping, we investigated whether there
were other cis elements repressing splicing at A2. Inspection of
noncoding exon 3 revealed that there were three motifs with
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FIG. 2. Mutagenesis of 59 splice site D3 toward the consensus 59 splice site sequence (panels A and B) and putative silencers (panels C and
D) increases splicing at 39 splice site A2 and inclusion of noncoding exon 2. RT-PCR analyses of ;4.0-kb (A and C) and ;1.8-kb (B and D)
mRNAs from cells transfected with wild-type and mutant plasmids (pDPSP and pSPD3up in panels A and B; pDPSP and pSPRS in panels C and
D) were performed. Mock-transfected cell mRNA was analyzed in parallel. Denaturing PAGE of 32P-labeled PCR products was performed as
described in Materials and Methods. The mutated sequences in each case are shown below the wild-type NL4-3 sequence, and the changes are
underlined. The PyUAG sequences are shown in italic type. RNA species are designated with exon numbers (and letters) as in Fig. 1. Note in
panels A and C that RNA species 1.3.4aI and 1.3.4bI were not separated. The locations on the gel of DNA ladder bands are shown on the left.
8490 BILODEAU ET AL. J. VIROL.
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the general consensus sequence PyUAG. These motifs have
sequence homology with previously described ESS elements in
the two tat coding exons (42). Previous data indicated that
mutations of the AG within this consensus sequence inhibited
ESS activity in the tat coding exons (41, 42). To test for a
similar effect in noncoding exon 3, we mutated all three of the
AGs within the PyUAG motifs to CU. The wild-type and
mutated plasmids were transfected into HeLa cells, and the
singly and multiply spliced mRNA species were analyzed by
RT-PCR as described above (Fig. 2C and D). For the ;4-kb
mRNA class, there was an increase in the level of Vpr mRNA
(1.3I) in the mutant-transfected cells, and almost all of the
;4.0-kb env mRNA species contained noncoding exon 3, in-
dicating that exon inclusion was almost complete (Fig. 2C, lane
3). As shown in Fig. 2D, lane 3, similar results were obtained
with the ;1.8-kb spliced mRNA species; almost all of these
mRNAs in mutant-transfected cells contained noncoding exon
3. These results strongly suggested that, in addition to the
flanking nonconsensus 59 splice site D3, exon 3 contains an
ESS element whose repressive effect on splice site A2 is re-
lieved by mutagenesis.
HIV-1 noncoding exon 3 contains an ESS element. To fur-
ther establish that the element in noncoding exon 3 was indeed
an ESS, we performed additional experiments using in vitro
splicing assays with HeLa cell nuclear extracts. We first created
wild-type and mutant minigene constructs containing exon 3
(pHS3-ESSV and pHS3-ESSVx, respectively) (Fig 3A). These
minigene templates were transcribed with phage T3 polymer-
FIG. 3. Analysis of the presence of an ESS in exon 3 by in vitro splicing assays. (A) The pHS3-ESSV template construct contains the indicated
regions of pNL4-3. Shown are 59 splice site D1 and 39 splice site A2. The location of the T3 phage polymerase promoter is also shown. The location
and the sequence of the putative ESS element are shown with the locations of the mutations underlined. RNA substrates were synthesized from
the template as described in Materials and Methods. (B) In vitro splicing of 32P-labeled HIV-1 HS3-ESSV and HS3-ESSVx substrates was analyzed
by denaturing PAGE. The positions of the RNA precursor and the spliced product are marked. (C) Ratios of radioactivity in the spliced product
compared to that in the unspliced RNA precursor were determined for mutant and wild-type substrates. The results are based on six independent
experiments. Standard deviations are shown by error bars.
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ase, and the RNA transcripts were used as substrates for in
vitro splicing assays. Mutagenesis of all three of the exon 3 AG
sequences, as in the pDPSRS construct used in the in vivo
transfection experiments described above, resulted in two- to
threefold increases in the ratio of spliced to unspliced RNAs
(Fig. 3B and C). These results were consistent with the hypoth-
esis that exon 3 contains an ESS and that mutagenesis of the
element results in increased splicing at 39 splice site A2.
If the sequence in noncoding exon 3 is an ESS, it should act
to inhibit splicing when placed into a heterologous context. To
this end, we replaced ESS2 in the first HIV-1 tat coding exon
with a 24-nt noncoding exon 3 sequence containing the three
PyUAG motifs. The resulting plasmid minigene construct,
shown in Fig. 4A, was used as a template for the synthesis of in
vitro splicing substrates. The data shown in Fig. 4B, lane 2,
indicated that splicing at 39 splice site A3 was indeed inhibited.
We found that splicing at splice site A3 of substrate HS1-ESSV
with the exon 3 insertion was consistently lower than that of the
wild-type HS1-ESS2 substrate containing the wild-type ESS2
element (compare lanes 1 and 2 of Fig. 4B). From these re-
sults, we concluded that the noncoding exon 3 sequence was an
ESS, which we named ESSV, and that it had a stronger silenc-
ing effect on splicing at splice site A3 than did ESS2. This
silencing was dependent on the sequence of ESSV, since mu-
tagenesis of all three AG sequences abrogated the splicing
inhibition (compare lanes 2 and 3 of Fig. 4B).
Evidence that ESSV and ESS2 bind to common cellular
factors. If ESSV is an authentic splicing silencer, then it would
be expected to bind to cellular factors, as do other ESS ele-
ments. We have previously shown that preincubation with ex-
cess competitor RNA containing ESS2 increases splicing at the
tat 39 splice site (A3) of RNA splicing substrates containing
this element (4). In data not shown, we found that preincuba-
tion with RNA containing wild-type ESSV caused relief of
splicing inhibition of substrate HS1-ESSV, whereas preincuba-
tion with the same amount of mutant ESSV-containing RNA
did not significantly affect splicing. Interestingly, preincubation
with competitor RNA containing ESS2 also resulted in in-
creased splicing of HS1-ESSV RNA. These results supported
the hypothesis that ESSV binds a cellular factor(s) and that
ESS2 and ESSV share this factor(s), necessary for this inhibi-
tion.
To further test this hypothesis, we performed experiments in
which we depleted nuclear extracts of the putative factors by
binding to RNAs containing splicing silencers. Competitor
ESS RNAs were biotinylated and coupled to streptavidin-
coated paramagnetic beads. HeLa cell nuclear extracts were
incubated with the RNA-beads, the beads containing bound
factors were removed, and the treated extracts were used for
splicing reactions. We first compared the splicing of RNA
substrates containing ESSV (HS1-ESSV) in nuclear extracts
which had been preincubated with wild-type and mutant ESSV
RNAs coupled to beads. As shown in Fig. 4B, there was little
splicing of HS1-ESSV in untreated extracts (Fig. 5A, lane 1).
In extracts preincubated with wild-type ESSV RNA coupled to
beads, there was a striking increase in the amount of splicing of
HS1-ESSV, indicating that a factor or factors inhibiting splic-
ing at 39 splice site A3 had been removed (Fig. 5A, lane 2). In
contrast, there was only a small increase in the amount of
splicing when extracts were preincubated with mutant RNA
coupled to beads (Fig. 5A, lane 3). As expected, the mutagen-
esis of ESSV (substrate HS1-ESSVx) relieved the inhibition of
splicing in untreated extracts (Fig. 5A, lane 4), and splicing of
this substrate was similar in extracts preincubated with either
wild-type or mutant ESSV RNA coupled to beads (Fig. 5A,
lanes 5 and 6).
To confirm that ESS2 and ESSV bind to common factors, we
treated HeLa cell nuclear extracts with beads coupled to ESS2
and mutant ESS2 RNAs. As expected, there was relief of
splicing inhibition of substrates containing ESS2 (Fig. 5B, com-
pare lanes 1 and 2). The results indicated that there was also
relief of splicing inhibition of substrates containing ESSV
(compare lanes 4 and 5 of Fig. 5B). In extracts that had been
preincubated with beads coupled to mutated ESS2 RNA, there
was only a small increase in the splicing of substrates contain-
ing ESS2 or ESSV (Fig. 5B, lane 3 or 6, respectively). In
contrast, the splicing of substrates containing mutated ESSV
(HS1-
ESSVx) was similar in both treated and untreated extracts
(Fig. 5B, lanes 7 to 9). These results reinforced the hypothesis
that the splicing silencers in tat exon 2 and noncoding exon 3
bind to common factors.
Specific depletion of cellular hnRNP A/B proteins by ESSV
RNA-beads. Previous studies have indicated that members of
the hnRNP A/B protein family mediate splicing inhibition of
HIV-1 substrates containing ESS2 (11). We examined proteins
FIG. 4. The ESSV sequence acts to inhibit splicing in a heterolo-
gous context. (A) Schematic representation of minigene template con-
structs containing 59 splice site D1 and 39 splice site A3 (3). These
constructs contain either ESS2, ESSV, or ESSVx. (B) 32P-labeled
RNA substrates HS1-ESS2, HS1-ESSV, and HS1-ESSVx were synthe-
sized and RNA splicing was performed as described in Materials and
Methods. Products of in vitro splicing of substrates were analyzed on
denaturing polyacrylamide gels. The positions of the precursor and the
spliced product are marked.
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in untreated extracts and in extracts treated with wild-type or
mutated ESSV RNA-beads to test for selective depletion of
proteins in the size range of the hnRNP A/B proteins. As
shown in Fig. 6A, several differences in the 30- to 40-kDa
molecular mass range between the ESSV and ESSVx lanes
were seen in the Coomassie blue-stained SDS-PAGE patterns.
Extracts treated with either wild-type or mutant RNA-beads
were depleted of these proteins, but the effect was selectively
greater when the wild-type RNA was used.
To identify these proteins, we performed Western blotting
using three antibodies directed against hnRNPs A1 and A1B,
hnRNP A2, and hnRNP B1 (Fig. 6B). In extracts treated with
either wild-type or mutant RNA-beads, there were reductions
in the amounts of hnRNP A/B proteins relative to those in
untreated extracts. However, in each case, there were further
reductions in the amounts of hnRNPs detected in extracts
treated with wild-type ESSV RNA-beads compared with the
mutant ESSV RNA-beads. These results imply that both wild-
type and mutant RNAs bind the hnRNPs but that the affinity
for the wild-type ESSV is greater than that for the mutant
ESSV. The binding data correlate with the data shown in Fig.
5A, which showed small increases in the splicing of ESSV-
containing substrates in extracts treated with mutant ESSV
RNA-beads but significantly greater increases in extracts
treated with wild-type ESSV RNA-beads.
In order to estimate the concentrations of hnRNP A1 re-
maining in the extracts treated with wild-type and mutant
ESSV RNA-beads, aliquots from nondepleted extracts and
proteins from extracts depleted with either ESSV or ESSVx
RNA-beads were separated by SDS-PAGE. The amounts of
hnRNP A1 were then estimated based on a comparison of the
intensities of Western blot staining using anti-A1 antibody and
the intensities using known amounts of purified hnRNP A1
(Fig. 6C). The results indicated the following approximate
hnRNP A1 concentrations in the nuclear extracts: nonde-
pleted, 7 mM; ESSV RNA-bead depleted, 1 mM; and ESSVx
RNA-bead depleted, 2 mM. These results reinforced the con-
clusion that hnRNP A/B proteins bind to both wild-type and
mutant ESSV RNAs. However, there appeared to be an ap-
proximate twofold increase in binding to the wild-type se-
quence, resulting in a preferential depletion of A/B hnRNPs
from the nuclear extracts treated with the wild-type RNA-
beads.
Addition of A/B hnRNPs to depleted extracts restores spe-
cific splicing inhibition. To confirm the hypothesis that splicing
inhibition by ESSV is mediated by preferential binding of
FIG. 5. Depletion of HeLa cell nuclear extracts with ESSV and ESS2 RNAs removes a common inhibitory cellular factor or factors. In vitro
splicing of HS1-ESSV, HS1-ESSVx, or HS1-ESS2 substrates was carried out by use of nondepleted nuclear extracts and nuclear extracts depleted
with ESSV- or ESSVx-biotinylated RNAs (A) or ESS2- or ESS2x-biotinylated RNAs (B) immobilized on paramagnetic beads (Beads-RNA) as
described in Materials and Methods. The positions of the precursor and the spliced product are marked.
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hnRNP A/B proteins, we added back exogenous hnRNP A/B
proteins to extracts depleted with wild-type ESSV RNA and
tested these extracts for the restoration of splicing inhibition
(Fig. 7). The amounts of hnRNPs added back to the wild-type
ESSV RNA-depleted nuclear extracts restored the final con-
centration in the splicing reactions to approximately the level
of the protein in extracts treated with mutant ESSV RNA-
beads. As expected, substrates containing either wild-type or
mutant ESSV silencers were spliced similarly in the depleted
extracts (compare lanes 1 and 2 of Fig. 7). When hnRNP A/B
proteins (A1, A1B, A2, and B1) were individually added back
to the depleted extracts, repression of splicing was restored to
the substrates with the wild-type but not the mutant silencer.
The addition of control proteins GST-UP1 (hnRNP A1 con-
taining its two RNA recognition motifs but lacking the C-
terminal glycine-rich domain) and GST alone did not affect
splicing. We also added back untagged UP1 and showed that
this protein also has no effect on the splicing of substrates with
the wild-type or the mutant silencers (data not shown). These
results indicated that hnRNP A/B proteins are necessary and
sufficient to restore the specific splicing inhibition by ESSV.
These data also indicate that this inhibition occurs at physio-
logical protein concentrations.
DISCUSSION
Two elements act in concert to regulate splicing at HIV-1 39
splice site A2, which defines the 59 border of noncoding exon
3. The first element is 59 splice site D3, which defines the 39
boundary of the exon and is a weak splice site. The second
element consists of silencer sequences within the exon. When
we mutated splice site D3 to change it to a consensus 59 splice
site, there were increases in both inclusion of noncoding exon
3 in multiply spliced mRNAs and usage of 39 splice site A2 in
singly spliced mRNAs. These results can be explained by the
exon bridging hypothesis, which proposes that U1 snRNP
binding to the downstream 59 splice site acts to increase splic-
ing efficiency at the upstream flanking 39 splice site (9, 22, 36).
FIG. 6. Selective depletion of inhibitory proteins in HeLa cell nuclear extracts with ESSV RNA-beads. (A) Samples (50 mg) from nondepleted
nuclear extracts and nuclear extracts depleted with either ESSV or ESSVx paramagnetic bead-immobilized RNAs were separated by SDS–10%
PAGE and stained with Coomassie blue. Circles on the right indicate differences between the ESSV RNA-beads and the ESSVx RNA-beads.
Apparent molecular weights (in thousands) are shown on the left. (B) Western blot analyses of proteins in depleted and nondepleted extracts were
carried out with the indicated anti-hnRNP antibodies as described in Materials and Methods. For the analyses with anti-hnRNP A1 and
anti-hnRNP B1 antibodies, 20 mg of protein from the depleted or nondepleted extracts was analyzed. For the analysis with anti-hnRNP A2
antibody, 50 mg of protein from the depleted or nondepleted extracts was analyzed. The anti-hnRNP A2 antiserum also detects hnRNP A1. (C)
Aliquots (1 to 8 ml) from HeLa cell nuclear extracts (HNE) nondepleted or depleted with either wild-type (ESSV) or mutant (ESSVx) RNA bound
to beads were electrophoresed, and Western blot analysis was carried out using anti-hnRNP A1 antibody.
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According to this hypothesis, changing splice site D3 to a
consensus 59 splice site would increase the affinity of U1
snRNP for this splice site and thus increase the efficiency of
splicing at 39 splice site A2. This prediction is consistent with
what our data showed. The weak effect of nonconsensus 59
splice site D3 on splicing at 39 splice site A2 may contribute to
the relatively low singly spliced Vpr mRNA levels and to skip-
ping of exon 3. Alternatively, skipping of exon 3 may result
from cis competition, in which consensus 59 splice site D1 is
normally favored over nonconsensus 59 splice site D3 for the
alternative 39 splice sites A3, A4a, A4b, A4c, and A5 (Fig. 1A).
Consistent with the importance of this nonconsensus 59 splice
site, the sequence of splice site D3 is conserved in all se-
quenced strains of HIV-1 (27). A similar mechanism may con-
tribute to the low efficiency of splicing at 39 splice site A1,
which flanks noncoding exon 2. Consistent with this hypothesis,
we have found that improvement of nonconsensus 59 splice site
D2 immediately downstream of noncoding exon 2 to a consen-
sus splice site (AG/GUGAAG to AG/GUGAGU) results in
increased inclusion of this exon (P. Bilodeau and C. M. Stoltz-
fus, unpublished data).
Splicing efficiency at 39 splice site A2 is also regulated by
ESS elements. We showed that mutagenesis of the three
PyUAG motifs within noncoding exon 3 abrogated the silenc-
ing activity of ESSV. Using in vitro splicing assays, we found
that mutagenesis of each motif individually resulted in only
small increases in splicing that were not significantly different
from the results seen with the wild type (Bilodeau and Stoltz-
fus, unpublished). Significant differences were seen only when
all three AGs within the 24-nt ESSV element were mutated. In
this regard, it is of interest that the three PyUAG sequences in
noncoding exon 3 are conserved in most sequenced HIV-1
strains belonging to the major HIV group (group M) (27).
Other HIV-1 ESS elements also contain the consensus se-
quence UAG or PyUAG. We have previously shown that
HIV-1 tat exon 2 contains ESS2, whose core sequence is CUA
GACUAGA, and tat exon 3 contains ESS3, which contains the
sequence UUAG. In each case, mutagenesis of the AG
dinucleotides results in abrogation of the silencing effect (41,
42). HIV-1 cryptic exon 6D inclusion has been shown to be
activated by a U-to-C mutation at the underlined base in the
sequence CAAUAGUAGUAG (46). This latter sequence may
also be an ESS element.
The evidence presented here also indicates that the ESS
elements downstream of both the Vpr and the Tat splice sites
compete for the same cellular factors. We have shown above
that these shared factors are members of the A/B hnRNP
family. Thus, our data agree with previous reports implicating
A/B hnRNP family members as mediators of splicing inhibition
by the ESS in tat exon 2 (ESS2) (11, 14). hnRNP A1 has also
been shown to bind to UAGG in the K-SAM exon of fibroblast
growth factor receptor 2 and to mediate splicing silencing of
this alternative exon (14). Recent data have indicated that the
binding of A/B hnRNPs to a splicing silencer within alternative
exon 16 of protein 4.1R pre-mRNA is necessary for splicing
repression of the 39 splice site bordering exon 16 (J. Conboy,
personal communication).
These previous results and the results reported here suggest
that members of the hnRNP A/B protein family binding to ESS
elements coordinately repress HIV-1 splicing. Thus, HIV-1
exploits these proteins as a means to limit the amount of
splicing at both Tat 39 splice sites and Vpr 39 splice sites.
hnRNP A/B proteins are ubiquitous, and this fact may allow
the repression of HIV-1 splicing in a variety of cell types. Our
data and those of Caputi et al. (11) indicate that, as determined
by in vitro splicing assays, all members of the hnRNP A/B
protein family, i.e., hnRNPs A1, A1B, A2, and B1, are able to
mediate HIV-1 ESS splicing inhibition. It is of interest that
hnRNP A1B, which is an alternatively spliced isoform of
hnRNP A1, has equivalent silencer activity in the alternative
splicing of HIV-1 pre-mRNAs (11; this study), whereas it has
very limited activity for 59 splice site switching (33). In prelim-
inary experiments, we have found that the splicing of HIV-1
Tat mRNA is repressed in the mouse erythroleukemia cell line
CB3 despite the lack of detectable hnRNP A1 and A1B ex-
pression in these cells (7, 47). Mutagenesis of ESS2 relieved
this repression (J. Domsic and C. M. Stoltzfus, unpublished
data). These data suggest that other members of the hnRNP
A/B protein family (i.e., hnRNPs A2 and B1) are able to
substitute for hnRNPs A1 and A1B in vivo as well as in vitro.
Recent data have indicated that hnRNP A1 binds to splicing
silencer elements within human CD44 exon v6 and downregu-
FIG. 7. Reconstitution of splicing inhibition by addition of hnRNP A/B proteins to depleted extracts. HS1-ESSV and HS1-ESSVx RNA
substrates were spliced in ESSV RNA-bead-depleted HeLa cell nuclear extracts in the presence of 900 ng of the indicated hnRNPs. Splicing was
also carried out after the addition of the same amounts of control proteins: UP1-GST (two RNA recognition motifs of hnRNP A1 fused to GST)
in lanes 11 and 12 and GST alone in lanes 13 and 14. The positions of the precursor and the spliced product are marked.
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lates the splicing of this exon (26, 31). Interestingly, this re-
pression was relieved by the expression of either oncogenic
Ras or oncogenic proteins that are in the Ras effector pathway
(31). Thus, in this case, oncogenic signaling appears to inter-
fere with hnRNP A1-mediated silencing. Inclusion of variant
exons in CD44 mRNAs is also increased upon activation of
normal lymphocytic and dendritic cells (5, 29, 45). It is possible
that interference with hnRNP A/B protein silencing upon cell
activation is a potential mechanism for increasing the efficiency
of HIV-1 splicing, resulting in increased Tat and Vpr mRNA
levels in some cell types and at different times after infection.
However, CD44 exon v5 does not contain consensus PyUAG
sequences, and the splicing silencing activity appears to be
spread throughout the 118-nt exon rather than localized, as in
the HIV-1 genome (26, 31). Thus, the mechanism by which
hnRNP A1 inhibits CD44 splicing may differ from that used in
HIV-1 splicing.
ESS elements and members of the hnRNP A/B protein
family also play important roles in the replication of other
RNA viruses. Borna disease virus is a nonsegmented negative-
strand RNA virus which replicates in the nucleus and whose
RNA undergoes splicing. It has been shown that the utilization
of one of the Borna disease virus 39 splice sites (SA3) is reg-
ulated by an ESS element downstream of this splice site. This
ESS contains two PyUAG motifs, and deletion of these motifs
abrogates the silencer activity (44). Thus, this ESS is also likely
to bind to members of the hnRNP A/B protein family. hnRNP
A1 has been shown to specifically bind to UUAG sequences
within the RNA of the coronavirus mouse hepatitis virus, the
replication of which occurs in the cytoplasm. This binding is
required for the regulation of viral RNA transcription and
replication (28, 40). The various roles played by hnRNP A/B
proteins in cells and during the replication of viruses suggest
that these proteins are components of several different com-
plexes that act in a regulatory fashion at different steps of viral
and cellular RNA processing as well as viral RNA synthesis.
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